All In Biotech

Drug Trial Radar · NCT00335452

Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS

Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.

Last checked: Nov 20, 2026Latest source record: Nov 18, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 25,086 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

25,086

Actual

Start

Jun 2006

Primary completion

Sep 2009

Study completion Sep 2009

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Jun 9, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a percutaneous coronary intervention (PCI).

Conditions

  • Acute Coronary Disease
  • Angina Unstable

Interventions

  • ClopidogrelDrug

    oral administration

  • acetylsalicyclic acid (ASA)Drug

    oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen ComparisonTime frame: 30 days
  2. First Occurrence of CV Death / MI / Stroke - ASA Dose ComparisonTime frame: 30 days
  3. First Occurrence of CV Death / MI / Stroke - Interaction Clopidogrel Treatment Regimen and ASA Dose LevelTime frame: 30 days
  4. First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison in PCI SubgroupTime frame: 30 days

Locations

38 sites in 38 countries. Site status is shown where the registry gives one.

  • Sanofi-Aventis Administrative Office

    Bridgewater, New Jersey

  • Sanofi-Aventis Administrative Office

    Buenos Aires, Argentina

  • sanofi-aventis Australia & New Zealand administrative office

    Macquarie Park, Australia

  • Sanofi-Aventis Administrative Office

    Vienna, Austria

  • Sanofi-Aventis Administrative Office

    Diegem, Belgium

  • Sanofi-Aventis Administrative Office

    São Paulo, Brazil

  • Sanofi-Aventis Administrative Office

    Sofia, Bulgaria

  • Sanofi-Aventis Administrative Office

    Laval, Canada

  • Sanofi-Aventis Administrative Office

    Santiago, Chile

  • Sanofi-Aventis Administrative Office

    Beijing, China

  • Sanofi-Aventis Administrative Office

    Zagreb, Croatia

  • Sanofi-Aventis Administrative Office

    Prague, Czechia

  • Sanofi-Aventis Administrative Office

    Tallinn, Estonia

  • Sanofi-Aventis Administrative Office

    Helsinki, Finland

  • Sanofi-Aventis Administrative Office

    Paris, France

  • Sanofi-Aventis Administrative Office

    Berlin, Germany

  • Sanofi-Aventis Administrative Office

    Athens, Greece

  • Sanofi-Aventis Administrative Office

    Mumbai, India

  • Sanofi-Aventis Administrative Office

    Dublin, Ireland

  • Sanofi-Aventis Administrative Office

    Netanya, Israel

  • Sanofi-Aventis Administrative Office

    Milan, Italy

  • Sanofi-Aventis Administrative Office

    Riga, Latvia

  • Sanofi-Aventis Administrative Office

    Vilnius, Lithuania

  • Sanofi-Aventis Administrative Office

    Kuala Lumpur, Malaysia

  • Sanofi-Aventis Administrative Office

    México, Mexico

  • Sanofi-Aventis Administrative Office

    Gouda, Netherlands

  • Sanofi-Aventis Administrative Office

    Warsaw, Poland

  • Sanofi-Aventis Administrative Office

    Bucharest, Romania

  • Sanofi-Aventis Administrative Office

    Moscow, Russia

  • Sanofi-Aventis Administrative Office

    Singapore, Singapore

  • Sanofi-Aventis Administrative Office

    Brastislava, Slovakia

  • Sanofi-Aventis Administrative Office

    Midrand, South Africa

  • Sanofi-Aventis Administrative Office

    Seoul, South Korea

  • Sanofi-Aventis Admnistrative Office

    Madrid, Spain

  • Sanofi-Aventis Administrative Office

    Bromma, Sweden

  • Sanofi-Aventis Administrative Office

    Geneva, Switzerland

  • Sanofi-Aventis Administrative Office

    Istanbul, Turkey (Türkiye)

  • Sanofi-Aventis Administrative Office

    Guildford, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.